Proteome Sciences PLC AGM Statement (6438Z)
17 Maio 2023 - 3:00AM
UK Regulatory
TIDMPRM
RNS Number : 6438Z
Proteome Sciences PLC
17 May 2023
17 May 2023
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Annual General Meeting (AGM) Statement
At the Company's AGM being held today at 12.00 noon, the
Chairman, Christopher Pearce, will make the following
statement:
"Proteome Sciences had a strong performance in the year ended 31
December 2022 with total revenue increasing by 52% to GBP7.78m
(2021: GBP5.13m). Biomarker services grew by 45% to GBP2.75m and
TMT(R)/TMTpro(TM) revenues increased 56% to GBP5.03m with adjusted
EBITDA rising 79% to GBP2.43m. The cash position increased by
GBP1.6m to GBP3.99m. These results include the costs incurred for
the investment we have made in additional instrumentation and
skilled personnel in our workforce, to promote the strategic
decision to introduce our single cell proteomics ("SCP") platform
in 2023 and to undertake the development of new and complementary
range of chemical tags to our TMT(R)/TMTpro(TM) reagents. Both new
offerings are expected to expand our growth in revenue and
recognition of our expertise in the marketplace.
The Board is confident that the progress over the recent years
has created an excellent platform for further development of the
Group. Following the investment made over the last two years, a
strong order book, new projects, high customer interest, our
healthy cash position and recently announced expansion into the US,
the Group has a strong base for 2023 and beyond. Proteome Sciences
is well set to achieve a step-change in growth which gives the
Board increased confidence that the business can continue to
significantly grow revenue and EBITDA in the coming years."
For further information:
Proteome Sciences plc
Dr. Mariola Soehngen, Chief Executive Officer Tel: +44 (0)20 7043 2116
Dr. Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer
Abdelghani Omari, Chief Financial Officer
Allenby Capital Limited (Nominated Adviser & Broker)
John Depasquale / Jeremy Porter (Corporate Tel: +44 (0) 20 3328
Finance) 5656
Tony Quirke / Stefano Aquilino (Equity Sales
& Corporate Broking)
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMAFMLTMTBBBAJ
(END) Dow Jones Newswires
May 17, 2023 02:00 ET (06:00 GMT)
Proteome Sciences (AQSE:PRM.GB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Proteome Sciences (AQSE:PRM.GB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024